nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—CYP2B6—Thiotepa—urinary bladder cancer	0.131	0.214	CbGbCtD
Methadone—ABCB1—Mitomycin—urinary bladder cancer	0.0883	0.145	CbGbCtD
Methadone—CYP3A4—Thiotepa—urinary bladder cancer	0.0401	0.0658	CbGbCtD
Methadone—CYP2B6—Cisplatin—urinary bladder cancer	0.036	0.0591	CbGbCtD
Methadone—CYP2C8—Fluorouracil—urinary bladder cancer	0.0321	0.0527	CbGbCtD
Methadone—CYP3A5—Etoposide—urinary bladder cancer	0.0279	0.0458	CbGbCtD
Methadone—CYP2C8—Etoposide—urinary bladder cancer	0.0268	0.044	CbGbCtD
Methadone—ABCB1—Gemcitabine—urinary bladder cancer	0.0254	0.0417	CbGbCtD
Methadone—CYP1A2—Fluorouracil—urinary bladder cancer	0.0249	0.0408	CbGbCtD
Methadone—CYP2B6—Doxorubicin—urinary bladder cancer	0.0241	0.0396	CbGbCtD
Methadone—CYP2C9—Fluorouracil—urinary bladder cancer	0.0224	0.0368	CbGbCtD
Methadone—CYP1A2—Etoposide—urinary bladder cancer	0.0208	0.0341	CbGbCtD
Methadone—CYP2C9—Cisplatin—urinary bladder cancer	0.019	0.0312	CbGbCtD
Methadone—ABCB1—Cisplatin—urinary bladder cancer	0.0185	0.0303	CbGbCtD
Methadone—ABCB1—Etoposide—urinary bladder cancer	0.0181	0.0298	CbGbCtD
Methadone—ABCB1—Doxorubicin—urinary bladder cancer	0.0124	0.0203	CbGbCtD
Methadone—ABCB1—Methotrexate—urinary bladder cancer	0.012	0.0197	CbGbCtD
Methadone—CYP2D6—Doxorubicin—urinary bladder cancer	0.0117	0.0191	CbGbCtD
Methadone—CYP3A4—Etoposide—urinary bladder cancer	0.0109	0.0178	CbGbCtD
Methadone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00742	0.0122	CbGbCtD
Methadone—CYP2C19—urine—urinary bladder cancer	0.00379	0.0899	CbGeAlD
Methadone—CYP1A2—urine—urinary bladder cancer	0.00309	0.0734	CbGeAlD
Methadone—CYP2C9—urine—urinary bladder cancer	0.00293	0.0697	CbGeAlD
Methadone—OPRK1—prostate gland—urinary bladder cancer	0.00277	0.0658	CbGeAlD
Methadone—CHRNA10—vagina—urinary bladder cancer	0.00229	0.0544	CbGeAlD
Methadone—CYP3A4—urine—urinary bladder cancer	0.00224	0.0531	CbGeAlD
Methadone—CYP2D6—urine—urinary bladder cancer	0.0022	0.0523	CbGeAlD
Methadone—OPRD1—renal system—urinary bladder cancer	0.00197	0.0468	CbGeAlD
Methadone—CYP19A1—prostate gland—urinary bladder cancer	0.00166	0.0393	CbGeAlD
Methadone—CYP2C18—vagina—urinary bladder cancer	0.00158	0.0375	CbGeAlD
Methadone—OPRK1—female reproductive system—urinary bladder cancer	0.00151	0.0359	CbGeAlD
Methadone—CHRNA10—lymph node—urinary bladder cancer	0.00148	0.0352	CbGeAlD
Methadone—Benzphetamine—POR—urinary bladder cancer	0.00138	0.488	CrCbGaD
Methadone—CYP3A5—prostate gland—urinary bladder cancer	0.00107	0.0254	CbGeAlD
Methadone—CYP19A1—female reproductive system—urinary bladder cancer	0.000904	0.0215	CbGeAlD
Methadone—CYP2C8—renal system—urinary bladder cancer	0.000808	0.0192	CbGeAlD
Methadone—CYP1A2—renal system—urinary bladder cancer	0.000756	0.018	CbGeAlD
Methadone—CYP3A5—renal system—urinary bladder cancer	0.00073	0.0173	CbGeAlD
Methadone—CYP2B6—renal system—urinary bladder cancer	0.000725	0.0172	CbGeAlD
Methadone—CYP2C19—vagina—urinary bladder cancer	0.000671	0.0159	CbGeAlD
Methadone—CYP2C8—female reproductive system—urinary bladder cancer	0.000647	0.0154	CbGeAlD
Methadone—CYP2C8—vagina—urinary bladder cancer	0.000586	0.0139	CbGeAlD
Methadone—CYP2B6—female reproductive system—urinary bladder cancer	0.000581	0.0138	CbGeAlD
Methadone—CYP2C9—female reproductive system—urinary bladder cancer	0.000575	0.0137	CbGeAlD
Methadone—ABCB1—prostate gland—urinary bladder cancer	0.000569	0.0135	CbGeAlD
Methadone—CYP3A4—renal system—urinary bladder cancer	0.000548	0.013	CbGeAlD
Methadone—CYP2D6—renal system—urinary bladder cancer	0.000539	0.0128	CbGeAlD
Methadone—CYP19A1—lymph node—urinary bladder cancer	0.000529	0.0126	CbGeAlD
Methadone—CYP3A5—vagina—urinary bladder cancer	0.000528	0.0125	CbGeAlD
Methadone—CYP2B6—vagina—urinary bladder cancer	0.000525	0.0125	CbGeAlD
Methadone—ABCB1—seminal vesicle—urinary bladder cancer	0.000481	0.0114	CbGeAlD
Methadone—Tamoxifen—ESR2—urinary bladder cancer	0.000471	0.166	CrCbGaD
Methadone—CYP3A4—female reproductive system—urinary bladder cancer	0.000439	0.0104	CbGeAlD
Methadone—CYP2D6—female reproductive system—urinary bladder cancer	0.000432	0.0102	CbGeAlD
Methadone—ABCB1—epithelium—urinary bladder cancer	0.000418	0.00992	CbGeAlD
Methadone—Oxaprozin—PTGS2—urinary bladder cancer	0.000414	0.146	CrCbGaD
Methadone—Constipation—Thiotepa—urinary bladder cancer	0.000389	0.0019	CcSEcCtD
Methadone—Pain—Thiotepa—urinary bladder cancer	0.000389	0.0019	CcSEcCtD
Methadone—ABCB1—renal system—urinary bladder cancer	0.000388	0.0092	CbGeAlD
Methadone—Muscle spasms—Etoposide—urinary bladder cancer	0.000384	0.00188	CcSEcCtD
Methadone—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000382	0.00187	CcSEcCtD
Methadone—Oedema—Gemcitabine—urinary bladder cancer	0.000382	0.00187	CcSEcCtD
Methadone—Cardiac failure—Epirubicin—urinary bladder cancer	0.000381	0.00186	CcSEcCtD
Methadone—ABCB1—urethra—urinary bladder cancer	0.000381	0.00904	CbGeAlD
Methadone—Irritability—Methotrexate—urinary bladder cancer	0.00038	0.00185	CcSEcCtD
Methadone—Confusional state—Fluorouracil—urinary bladder cancer	0.000379	0.00185	CcSEcCtD
Methadone—Convulsion—Cisplatin—urinary bladder cancer	0.000378	0.00185	CcSEcCtD
Methadone—Oedema—Fluorouracil—urinary bladder cancer	0.000376	0.00183	CcSEcCtD
Methadone—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000376	0.00183	CcSEcCtD
Methadone—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000374	0.00183	CcSEcCtD
Methadone—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000374	0.00183	CcSEcCtD
Methadone—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000372	0.00181	CcSEcCtD
Methadone—Anxiety—Cisplatin—urinary bladder cancer	0.00037	0.00181	CcSEcCtD
Methadone—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000369	0.0018	CcSEcCtD
Methadone—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000368	0.0018	CcSEcCtD
Methadone—Tachycardia—Fluorouracil—urinary bladder cancer	0.000367	0.00179	CcSEcCtD
Methadone—Anorexia—Gemcitabine—urinary bladder cancer	0.000364	0.00178	CcSEcCtD
Methadone—Urticaria—Thiotepa—urinary bladder cancer	0.000361	0.00176	CcSEcCtD
Methadone—Vertigo—Etoposide—urinary bladder cancer	0.000359	0.00175	CcSEcCtD
Methadone—Abdominal pain—Thiotepa—urinary bladder cancer	0.000359	0.00175	CcSEcCtD
Methadone—Body temperature increased—Thiotepa—urinary bladder cancer	0.000359	0.00175	CcSEcCtD
Methadone—Anorexia—Fluorouracil—urinary bladder cancer	0.000358	0.00175	CcSEcCtD
Methadone—Hypotension—Gemcitabine—urinary bladder cancer	0.000357	0.00174	CcSEcCtD
Methadone—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000356	0.00174	CcSEcCtD
Methadone—Oedema—Cisplatin—urinary bladder cancer	0.000356	0.00174	CcSEcCtD
Methadone—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000354	0.00173	CcSEcCtD
Methadone—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000353	0.00172	CcSEcCtD
Methadone—Loss of consciousness—Etoposide—urinary bladder cancer	0.000351	0.00172	CcSEcCtD
Methadone—Hypotension—Fluorouracil—urinary bladder cancer	0.000351	0.00171	CcSEcCtD
Methadone—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000349	0.0017	CcSEcCtD
Methadone—Tachycardia—Cisplatin—urinary bladder cancer	0.000348	0.0017	CcSEcCtD
Methadone—Convulsion—Etoposide—urinary bladder cancer	0.000346	0.00169	CcSEcCtD
Methadone—Insomnia—Gemcitabine—urinary bladder cancer	0.000346	0.00169	CcSEcCtD
Methadone—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000344	0.00168	CcSEcCtD
Methadone—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.00034	0.00166	CcSEcCtD
Methadone—Insomnia—Fluorouracil—urinary bladder cancer	0.00034	0.00166	CcSEcCtD
Methadone—Somnolence—Gemcitabine—urinary bladder cancer	0.00034	0.00166	CcSEcCtD
Methadone—Anorexia—Cisplatin—urinary bladder cancer	0.00034	0.00166	CcSEcCtD
Methadone—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000339	0.00165	CcSEcCtD
Methadone—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000335	0.00163	CcSEcCtD
Methadone—Somnolence—Fluorouracil—urinary bladder cancer	0.000334	0.00163	CcSEcCtD
Methadone—Hypotension—Cisplatin—urinary bladder cancer	0.000333	0.00162	CcSEcCtD
Methadone—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000333	0.00162	CcSEcCtD
Methadone—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000332	0.00162	CcSEcCtD
Methadone—Confusional state—Etoposide—urinary bladder cancer	0.000329	0.00161	CcSEcCtD
Methadone—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000327	0.0016	CcSEcCtD
Methadone—Pain—Gemcitabine—urinary bladder cancer	0.000327	0.0016	CcSEcCtD
Methadone—Constipation—Gemcitabine—urinary bladder cancer	0.000327	0.0016	CcSEcCtD
Methadone—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000327	0.00159	CcSEcCtD
Methadone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000326	0.00159	CcSEcCtD
Methadone—Asthenia—Thiotepa—urinary bladder cancer	0.000326	0.00159	CcSEcCtD
Methadone—Pruritus—Thiotepa—urinary bladder cancer	0.000321	0.00157	CcSEcCtD
Methadone—Pain—Fluorouracil—urinary bladder cancer	0.000321	0.00157	CcSEcCtD
Methadone—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00032	0.00156	CcSEcCtD
Methadone—Tachycardia—Etoposide—urinary bladder cancer	0.000319	0.00155	CcSEcCtD
Methadone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000316	0.00154	CcSEcCtD
Methadone—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000315	0.00154	CcSEcCtD
Methadone—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000315	0.00154	CcSEcCtD
Methadone—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000313	0.00153	CcSEcCtD
Methadone—Anorexia—Etoposide—urinary bladder cancer	0.000311	0.00152	CcSEcCtD
Methadone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000311	0.00152	CcSEcCtD
Methadone—ABCB1—female reproductive system—urinary bladder cancer	0.00031	0.00737	CbGeAlD
Methadone—Decreased appetite—Cisplatin—urinary bladder cancer	0.00031	0.00151	CcSEcCtD
Methadone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00031	0.00151	CcSEcCtD
Methadone—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000308	0.0015	CcSEcCtD
Methadone—Drowsiness—Methotrexate—urinary bladder cancer	0.000307	0.0015	CcSEcCtD
Methadone—Hypotension—Etoposide—urinary bladder cancer	0.000305	0.00149	CcSEcCtD
Methadone—Pain—Cisplatin—urinary bladder cancer	0.000305	0.00149	CcSEcCtD
Methadone—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000302	0.00147	CcSEcCtD
Methadone—Dizziness—Thiotepa—urinary bladder cancer	0.0003	0.00147	CcSEcCtD
Methadone—Urticaria—Fluorouracil—urinary bladder cancer	0.000299	0.00146	CcSEcCtD
Methadone—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000297	0.00145	CcSEcCtD
Methadone—Sweating—Methotrexate—urinary bladder cancer	0.000294	0.00143	CcSEcCtD
Methadone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000294	0.00143	CcSEcCtD
Methadone—Weight increased—Epirubicin—urinary bladder cancer	0.000293	0.00143	CcSEcCtD
Methadone—Weight decreased—Epirubicin—urinary bladder cancer	0.000291	0.00142	CcSEcCtD
Methadone—Somnolence—Etoposide—urinary bladder cancer	0.00029	0.00142	CcSEcCtD
Methadone—Tamoxifen—ESR1—urinary bladder cancer	0.00029	0.102	CrCbGaD
Methadone—Vomiting—Thiotepa—urinary bladder cancer	0.000289	0.00141	CcSEcCtD
Methadone—Drowsiness—Epirubicin—urinary bladder cancer	0.000287	0.0014	CcSEcCtD
Methadone—Rash—Thiotepa—urinary bladder cancer	0.000286	0.0014	CcSEcCtD
Methadone—Dermatitis—Thiotepa—urinary bladder cancer	0.000286	0.0014	CcSEcCtD
Methadone—Headache—Thiotepa—urinary bladder cancer	0.000285	0.00139	CcSEcCtD
Methadone—Decreased appetite—Etoposide—urinary bladder cancer	0.000284	0.00138	CcSEcCtD
Methadone—Body temperature increased—Cisplatin—urinary bladder cancer	0.000282	0.00137	CcSEcCtD
Methadone—ABCB1—vagina—urinary bladder cancer	0.000281	0.00666	CbGeAlD
Methadone—Pain—Etoposide—urinary bladder cancer	0.000279	0.00136	CcSEcCtD
Methadone—Constipation—Etoposide—urinary bladder cancer	0.000279	0.00136	CcSEcCtD
Methadone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000277	0.00135	CcSEcCtD
Methadone—Sweating—Epirubicin—urinary bladder cancer	0.000275	0.00134	CcSEcCtD
Methadone—Asthenia—Gemcitabine—urinary bladder cancer	0.000274	0.00134	CcSEcCtD
Methadone—Phenylbutazone—PTGS2—urinary bladder cancer	0.000273	0.0966	CrCbGaD
Methadone—Weight increased—Doxorubicin—urinary bladder cancer	0.000271	0.00132	CcSEcCtD
Methadone—Pruritus—Gemcitabine—urinary bladder cancer	0.00027	0.00132	CcSEcCtD
Methadone—Nausea—Thiotepa—urinary bladder cancer	0.00027	0.00132	CcSEcCtD
Methadone—Weight decreased—Doxorubicin—urinary bladder cancer	0.000269	0.00131	CcSEcCtD
Methadone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000269	0.00131	CcSEcCtD
Methadone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000267	0.0013	CcSEcCtD
Methadone—Pruritus—Fluorouracil—urinary bladder cancer	0.000266	0.0013	CcSEcCtD
Methadone—Drowsiness—Doxorubicin—urinary bladder cancer	0.000265	0.0013	CcSEcCtD
Methadone—Visual impairment—Methotrexate—urinary bladder cancer	0.000265	0.00129	CcSEcCtD
Methadone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000262	0.00128	CcSEcCtD
Methadone—Bradycardia—Epirubicin—urinary bladder cancer	0.000262	0.00128	CcSEcCtD
Methadone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000262	0.00128	CcSEcCtD
Methadone—Urticaria—Etoposide—urinary bladder cancer	0.000259	0.00127	CcSEcCtD
Methadone—Body temperature increased—Etoposide—urinary bladder cancer	0.000258	0.00126	CcSEcCtD
Methadone—Abdominal pain—Etoposide—urinary bladder cancer	0.000258	0.00126	CcSEcCtD
Methadone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000257	0.00126	CcSEcCtD
Methadone—Asthenia—Cisplatin—urinary bladder cancer	0.000256	0.00125	CcSEcCtD
Methadone—Sweating—Doxorubicin—urinary bladder cancer	0.000254	0.00124	CcSEcCtD
Methadone—Dizziness—Fluorouracil—urinary bladder cancer	0.000248	0.00121	CcSEcCtD
Methadone—Visual impairment—Epirubicin—urinary bladder cancer	0.000248	0.00121	CcSEcCtD
Methadone—Chills—Methotrexate—urinary bladder cancer	0.000247	0.00121	CcSEcCtD
Methadone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000244	0.00119	CcSEcCtD
Methadone—Vomiting—Gemcitabine—urinary bladder cancer	0.000243	0.00119	CcSEcCtD
Methadone—Bradycardia—Doxorubicin—urinary bladder cancer	0.000243	0.00118	CcSEcCtD
Methadone—Rash—Gemcitabine—urinary bladder cancer	0.000241	0.00118	CcSEcCtD
Methadone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000241	0.00118	CcSEcCtD
Methadone—Hypersensitivity—Etoposide—urinary bladder cancer	0.00024	0.00117	CcSEcCtD
Methadone—Erythema—Methotrexate—urinary bladder cancer	0.00024	0.00117	CcSEcCtD
Methadone—Headache—Gemcitabine—urinary bladder cancer	0.000239	0.00117	CcSEcCtD
Methadone—Flushing—Epirubicin—urinary bladder cancer	0.000239	0.00117	CcSEcCtD
Methadone—Vomiting—Fluorouracil—urinary bladder cancer	0.000239	0.00117	CcSEcCtD
Methadone—Rash—Fluorouracil—urinary bladder cancer	0.000237	0.00116	CcSEcCtD
Methadone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000237	0.00116	CcSEcCtD
Methadone—Headache—Fluorouracil—urinary bladder cancer	0.000235	0.00115	CcSEcCtD
Methadone—Asthenia—Etoposide—urinary bladder cancer	0.000234	0.00114	CcSEcCtD
Methadone—Chills—Epirubicin—urinary bladder cancer	0.000231	0.00113	CcSEcCtD
Methadone—Pruritus—Etoposide—urinary bladder cancer	0.000231	0.00113	CcSEcCtD
Methadone—Arrhythmia—Epirubicin—urinary bladder cancer	0.00023	0.00112	CcSEcCtD
Methadone—Visual impairment—Doxorubicin—urinary bladder cancer	0.00023	0.00112	CcSEcCtD
Methadone—Nausea—Gemcitabine—urinary bladder cancer	0.000227	0.00111	CcSEcCtD
Methadone—Vomiting—Cisplatin—urinary bladder cancer	0.000227	0.00111	CcSEcCtD
Methadone—Rash—Cisplatin—urinary bladder cancer	0.000225	0.0011	CcSEcCtD
Methadone—Dermatitis—Cisplatin—urinary bladder cancer	0.000224	0.0011	CcSEcCtD
Methadone—Erythema—Epirubicin—urinary bladder cancer	0.000224	0.00109	CcSEcCtD
Methadone—Diarrhoea—Etoposide—urinary bladder cancer	0.000223	0.00109	CcSEcCtD
Methadone—Nausea—Fluorouracil—urinary bladder cancer	0.000223	0.00109	CcSEcCtD
Methadone—Flushing—Doxorubicin—urinary bladder cancer	0.000221	0.00108	CcSEcCtD
Methadone—Dizziness—Etoposide—urinary bladder cancer	0.000216	0.00105	CcSEcCtD
Methadone—Muscle spasms—Epirubicin—urinary bladder cancer	0.000216	0.00105	CcSEcCtD
Methadone—Vertigo—Methotrexate—urinary bladder cancer	0.000215	0.00105	CcSEcCtD
Methadone—Chills—Doxorubicin—urinary bladder cancer	0.000214	0.00104	CcSEcCtD
Methadone—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000213	0.00104	CcSEcCtD
Methadone—Nausea—Cisplatin—urinary bladder cancer	0.000212	0.00103	CcSEcCtD
Methadone—Convulsion—Methotrexate—urinary bladder cancer	0.000208	0.00101	CcSEcCtD
Methadone—Vomiting—Etoposide—urinary bladder cancer	0.000208	0.00101	CcSEcCtD
Methadone—Erythema—Doxorubicin—urinary bladder cancer	0.000207	0.00101	CcSEcCtD
Methadone—Agitation—Epirubicin—urinary bladder cancer	0.000206	0.00101	CcSEcCtD
Methadone—Rash—Etoposide—urinary bladder cancer	0.000206	0.001	CcSEcCtD
Methadone—Dermatitis—Etoposide—urinary bladder cancer	0.000206	0.001	CcSEcCtD
Methadone—Headache—Etoposide—urinary bladder cancer	0.000204	0.000998	CcSEcCtD
Methadone—Vertigo—Epirubicin—urinary bladder cancer	0.000201	0.000983	CcSEcCtD
Methadone—Syncope—Epirubicin—urinary bladder cancer	0.000201	0.000981	CcSEcCtD
Methadone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000199	0.000973	CcSEcCtD
Methadone—Palpitations—Epirubicin—urinary bladder cancer	0.000198	0.000967	CcSEcCtD
Methadone—Confusional state—Methotrexate—urinary bladder cancer	0.000197	0.000962	CcSEcCtD
Methadone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000197	0.000962	CcSEcCtD
Methadone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000195	0.000954	CcSEcCtD
Methadone—Convulsion—Epirubicin—urinary bladder cancer	0.000194	0.000948	CcSEcCtD
Methadone—Nausea—Etoposide—urinary bladder cancer	0.000194	0.000946	CcSEcCtD
Methadone—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000191	0.000934	CcSEcCtD
Methadone—Agitation—Doxorubicin—urinary bladder cancer	0.000191	0.00093	CcSEcCtD
Methadone—Anxiety—Epirubicin—urinary bladder cancer	0.00019	0.000928	CcSEcCtD
Methadone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000189	0.000922	CcSEcCtD
Methadone—Dry mouth—Epirubicin—urinary bladder cancer	0.000187	0.000911	CcSEcCtD
Methadone—Vertigo—Doxorubicin—urinary bladder cancer	0.000186	0.00091	CcSEcCtD
Methadone—Anorexia—Methotrexate—urinary bladder cancer	0.000186	0.00091	CcSEcCtD
Methadone—Syncope—Doxorubicin—urinary bladder cancer	0.000186	0.000908	CcSEcCtD
Methadone—Confusional state—Epirubicin—urinary bladder cancer	0.000184	0.0009	CcSEcCtD
Methadone—Palpitations—Doxorubicin—urinary bladder cancer	0.000183	0.000895	CcSEcCtD
Methadone—Oedema—Epirubicin—urinary bladder cancer	0.000183	0.000893	CcSEcCtD
Methadone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000183	0.000893	CcSEcCtD
Methadone—Hypotension—Methotrexate—urinary bladder cancer	0.000183	0.000892	CcSEcCtD
Methadone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000182	0.00089	CcSEcCtD
Methadone—ABCB1—lymph node—urinary bladder cancer	0.000182	0.00431	CbGeAlD
Methadone—Shock—Epirubicin—urinary bladder cancer	0.00018	0.000879	CcSEcCtD
Methadone—Convulsion—Doxorubicin—urinary bladder cancer	0.00018	0.000877	CcSEcCtD
Methadone—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000179	0.000874	CcSEcCtD
Methadone—Tachycardia—Epirubicin—urinary bladder cancer	0.000179	0.000872	CcSEcCtD
Methadone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000177	0.000863	CcSEcCtD
Methadone—Insomnia—Methotrexate—urinary bladder cancer	0.000177	0.000863	CcSEcCtD
Methadone—Anxiety—Doxorubicin—urinary bladder cancer	0.000176	0.000859	CcSEcCtD
Methadone—Anorexia—Epirubicin—urinary bladder cancer	0.000174	0.000851	CcSEcCtD
Methadone—Somnolence—Methotrexate—urinary bladder cancer	0.000174	0.000848	CcSEcCtD
Methadone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000173	0.000843	CcSEcCtD
Methadone—Hypotension—Epirubicin—urinary bladder cancer	0.000171	0.000834	CcSEcCtD
Methadone—Confusional state—Doxorubicin—urinary bladder cancer	0.000171	0.000833	CcSEcCtD
Methadone—Decreased appetite—Methotrexate—urinary bladder cancer	0.00017	0.000829	CcSEcCtD
Methadone—Oedema—Doxorubicin—urinary bladder cancer	0.000169	0.000826	CcSEcCtD
Methadone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000169	0.000826	CcSEcCtD
Methadone—Pain—Methotrexate—urinary bladder cancer	0.000167	0.000816	CcSEcCtD
Methadone—Shock—Doxorubicin—urinary bladder cancer	0.000167	0.000813	CcSEcCtD
Methadone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000166	0.000809	CcSEcCtD
Methadone—Insomnia—Epirubicin—urinary bladder cancer	0.000165	0.000808	CcSEcCtD
Methadone—Tachycardia—Doxorubicin—urinary bladder cancer	0.000165	0.000806	CcSEcCtD
Methadone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000164	0.000799	CcSEcCtD
Methadone—Somnolence—Epirubicin—urinary bladder cancer	0.000163	0.000794	CcSEcCtD
Methadone—Anorexia—Doxorubicin—urinary bladder cancer	0.000161	0.000788	CcSEcCtD
Methadone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000161	0.000786	CcSEcCtD
Methadone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00016	0.00078	CcSEcCtD
Methadone—Decreased appetite—Epirubicin—urinary bladder cancer	0.000159	0.000776	CcSEcCtD
Methadone—Hypotension—Doxorubicin—urinary bladder cancer	0.000158	0.000772	CcSEcCtD
Methadone—Pain—Epirubicin—urinary bladder cancer	0.000156	0.000764	CcSEcCtD
Methadone—Constipation—Epirubicin—urinary bladder cancer	0.000156	0.000764	CcSEcCtD
Methadone—Urticaria—Methotrexate—urinary bladder cancer	0.000155	0.000758	CcSEcCtD
Methadone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000155	0.000754	CcSEcCtD
Methadone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000155	0.000754	CcSEcCtD
Methadone—Insomnia—Doxorubicin—urinary bladder cancer	0.000153	0.000747	CcSEcCtD
Methadone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000151	0.000736	CcSEcCtD
Methadone—Somnolence—Doxorubicin—urinary bladder cancer	0.00015	0.000735	CcSEcCtD
Methadone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00015	0.00073	CcSEcCtD
Methadone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000147	0.000718	CcSEcCtD
Methadone—Urticaria—Epirubicin—urinary bladder cancer	0.000145	0.000709	CcSEcCtD
Methadone—Constipation—Doxorubicin—urinary bladder cancer	0.000145	0.000707	CcSEcCtD
Methadone—Pain—Doxorubicin—urinary bladder cancer	0.000145	0.000707	CcSEcCtD
Methadone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000145	0.000706	CcSEcCtD
Methadone—Body temperature increased—Epirubicin—urinary bladder cancer	0.000145	0.000706	CcSEcCtD
Methadone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000144	0.000703	CcSEcCtD
Methadone—Asthenia—Methotrexate—urinary bladder cancer	0.00014	0.000685	CcSEcCtD
Methadone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000139	0.000681	CcSEcCtD
Methadone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000138	0.000676	CcSEcCtD
Methadone—Pruritus—Methotrexate—urinary bladder cancer	0.000138	0.000675	CcSEcCtD
Methadone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000135	0.000658	CcSEcCtD
Methadone—Urticaria—Doxorubicin—urinary bladder cancer	0.000134	0.000656	CcSEcCtD
Methadone—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000134	0.000653	CcSEcCtD
Methadone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000134	0.000653	CcSEcCtD
Methadone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000134	0.000653	CcSEcCtD
Methadone—Asthenia—Epirubicin—urinary bladder cancer	0.000131	0.000641	CcSEcCtD
Methadone—Pruritus—Epirubicin—urinary bladder cancer	0.000129	0.000632	CcSEcCtD
Methadone—Dizziness—Methotrexate—urinary bladder cancer	0.000129	0.000631	CcSEcCtD
Methadone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000125	0.000611	CcSEcCtD
Methadone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000125	0.000609	CcSEcCtD
Methadone—Vomiting—Methotrexate—urinary bladder cancer	0.000124	0.000607	CcSEcCtD
Methadone—Rash—Methotrexate—urinary bladder cancer	0.000123	0.000602	CcSEcCtD
Methadone—Dermatitis—Methotrexate—urinary bladder cancer	0.000123	0.000601	CcSEcCtD
Methadone—Headache—Methotrexate—urinary bladder cancer	0.000122	0.000598	CcSEcCtD
Methadone—Asthenia—Doxorubicin—urinary bladder cancer	0.000121	0.000593	CcSEcCtD
Methadone—Dizziness—Epirubicin—urinary bladder cancer	0.000121	0.00059	CcSEcCtD
Methadone—Pruritus—Doxorubicin—urinary bladder cancer	0.00012	0.000585	CcSEcCtD
Methadone—Vomiting—Epirubicin—urinary bladder cancer	0.000116	0.000568	CcSEcCtD
Methadone—Nausea—Methotrexate—urinary bladder cancer	0.000116	0.000567	CcSEcCtD
Methadone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000116	0.000565	CcSEcCtD
Methadone—Rash—Epirubicin—urinary bladder cancer	0.000115	0.000563	CcSEcCtD
Methadone—Dermatitis—Epirubicin—urinary bladder cancer	0.000115	0.000563	CcSEcCtD
Methadone—Headache—Epirubicin—urinary bladder cancer	0.000115	0.000559	CcSEcCtD
Methadone—Dizziness—Doxorubicin—urinary bladder cancer	0.000112	0.000546	CcSEcCtD
Methadone—Nausea—Epirubicin—urinary bladder cancer	0.000109	0.00053	CcSEcCtD
Methadone—Vomiting—Doxorubicin—urinary bladder cancer	0.000108	0.000525	CcSEcCtD
Methadone—Rash—Doxorubicin—urinary bladder cancer	0.000107	0.000521	CcSEcCtD
Methadone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000107	0.00052	CcSEcCtD
Methadone—Headache—Doxorubicin—urinary bladder cancer	0.000106	0.000518	CcSEcCtD
Methadone—Nausea—Doxorubicin—urinary bladder cancer	0.000101	0.000491	CcSEcCtD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.98e-05	0.000141	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.98e-05	0.000141	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—NQO1—urinary bladder cancer	1.98e-05	0.000141	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—GPX1—urinary bladder cancer	1.96e-05	0.00014	CbGpPWpGaD
Methadone—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.95e-05	0.000139	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—IL2—urinary bladder cancer	1.94e-05	0.000138	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.93e-05	0.000137	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.93e-05	0.000137	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	1.93e-05	0.000137	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.92e-05	0.000136	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—FGFR3—urinary bladder cancer	1.91e-05	0.000136	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.85e-05	0.000132	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.85e-05	0.000132	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—ESR1—urinary bladder cancer	1.85e-05	0.000132	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CREBBP—urinary bladder cancer	1.85e-05	0.000132	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.85e-05	0.000131	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.84e-05	0.000131	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.84e-05	0.000131	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IGF1—urinary bladder cancer	1.83e-05	0.00013	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.83e-05	0.00013	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—EGFR—urinary bladder cancer	1.82e-05	0.000129	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	1.81e-05	0.000129	CbGpPWpGaD
Methadone—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.81e-05	0.000129	CbGpPWpGaD
Methadone—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.81e-05	0.000129	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.81e-05	0.000128	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.8e-05	0.000128	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.77e-05	0.000126	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—IL2—urinary bladder cancer	1.76e-05	0.000125	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TERT—urinary bladder cancer	1.76e-05	0.000125	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.76e-05	0.000125	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PTGS2—urinary bladder cancer	1.74e-05	0.000124	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—KRAS—urinary bladder cancer	1.72e-05	0.000122	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.71e-05	0.000121	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.71e-05	0.000121	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PPARG—urinary bladder cancer	1.69e-05	0.00012	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.69e-05	0.00012	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.69e-05	0.00012	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.68e-05	0.000119	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—RHOA—urinary bladder cancer	1.68e-05	0.000119	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.68e-05	0.000119	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.65e-05	0.000118	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	1.65e-05	0.000117	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.64e-05	0.000117	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.64e-05	0.000117	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	1.63e-05	0.000115	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.63e-05	0.000115	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CREBBP—urinary bladder cancer	1.62e-05	0.000115	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.62e-05	0.000115	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.61e-05	0.000115	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—FGFR3—urinary bladder cancer	1.61e-05	0.000115	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IGF1—urinary bladder cancer	1.6e-05	0.000114	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—EGFR—urinary bladder cancer	1.6e-05	0.000113	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—ESR1—urinary bladder cancer	1.57e-05	0.000111	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.56e-05	0.000111	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—ERBB2—urinary bladder cancer	1.55e-05	0.00011	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.54e-05	0.00011	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—TYMS—urinary bladder cancer	1.53e-05	0.000109	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PTEN—urinary bladder cancer	1.52e-05	0.000108	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	1.52e-05	0.000108	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	1.52e-05	0.000108	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—KRAS—urinary bladder cancer	1.51e-05	0.000107	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.5e-05	0.000107	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.5e-05	0.000106	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.48e-05	0.000105	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.48e-05	0.000105	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CXCL8—urinary bladder cancer	1.47e-05	0.000104	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PPARG—urinary bladder cancer	1.47e-05	0.000104	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—RHOA—urinary bladder cancer	1.47e-05	0.000104	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—HRAS—urinary bladder cancer	1.46e-05	0.000104	CbGpPWpGaD
Methadone—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.46e-05	0.000104	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—GPX1—urinary bladder cancer	1.45e-05	0.000103	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.45e-05	0.000103	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—EP300—urinary bladder cancer	1.45e-05	0.000103	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.45e-05	0.000103	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.45e-05	0.000103	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.44e-05	0.000102	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	1.43e-05	0.000101	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.42e-05	0.000101	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.42e-05	0.000101	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	1.41e-05	0.0001	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL2—urinary bladder cancer	1.41e-05	9.99e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.4e-05	9.96e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.4e-05	9.92e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.4e-05	9.91e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.39e-05	9.9e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.38e-05	9.81e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.38e-05	9.77e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CREBBP—urinary bladder cancer	1.37e-05	9.75e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCND1—urinary bladder cancer	1.37e-05	9.73e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.36e-05	9.68e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—ERBB2—urinary bladder cancer	1.36e-05	9.66e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IGF1—urinary bladder cancer	1.36e-05	9.63e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.35e-05	9.6e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—EGFR—urinary bladder cancer	1.35e-05	9.58e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.34e-05	9.52e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	1.33e-05	9.46e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MMP9—urinary bladder cancer	1.33e-05	9.45e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.33e-05	9.42e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.32e-05	9.4e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PTEN—urinary bladder cancer	1.32e-05	9.4e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.31e-05	9.31e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.3e-05	9.23e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCL8—urinary bladder cancer	1.29e-05	9.16e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.28e-05	9.12e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.28e-05	9.12e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—HRAS—urinary bladder cancer	1.28e-05	9.1e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—KRAS—urinary bladder cancer	1.27e-05	9.05e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.27e-05	8.99e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—EP300—urinary bladder cancer	1.26e-05	8.96e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.25e-05	8.86e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—RHOA—urinary bladder cancer	1.24e-05	8.82e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL2—urinary bladder cancer	1.23e-05	8.76e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.23e-05	8.73e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—SRC—urinary bladder cancer	1.23e-05	8.71e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.22e-05	8.65e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.21e-05	8.58e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.21e-05	8.57e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.2e-05	8.56e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCND1—urinary bladder cancer	1.2e-05	8.54e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MMP9—urinary bladder cancer	1.17e-05	8.29e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.16e-05	8.28e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.16e-05	8.26e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTEN—urinary bladder cancer	1.16e-05	8.25e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PTEN—urinary bladder cancer	1.16e-05	8.24e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.16e-05	8.24e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.16e-05	8.21e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.15e-05	8.19e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—ERBB2—urinary bladder cancer	1.15e-05	8.17e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.15e-05	8.15e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.15e-05	8.14e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.15e-05	8.14e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.14e-05	8.08e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.13e-05	8.06e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.13e-05	8.04e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.13e-05	8.03e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.12e-05	7.95e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.12e-05	7.95e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.12e-05	7.92e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.12e-05	7.92e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—EP300—urinary bladder cancer	1.11e-05	7.87e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—EP300—urinary bladder cancer	1.11e-05	7.86e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.1e-05	7.82e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MYC—urinary bladder cancer	1.1e-05	7.81e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.1e-05	7.8e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCL8—urinary bladder cancer	1.09e-05	7.74e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.09e-05	7.72e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—HRAS—urinary bladder cancer	1.08e-05	7.69e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.08e-05	7.69e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.08e-05	7.65e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—SRC—urinary bladder cancer	1.08e-05	7.64e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—EGFR—urinary bladder cancer	1.08e-05	7.64e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.07e-05	7.61e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.07e-05	7.57e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.06e-05	7.55e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.06e-05	7.51e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.05e-05	7.49e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.05e-05	7.49e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.05e-05	7.47e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.04e-05	7.42e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.04e-05	7.42e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.04e-05	7.42e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL2—urinary bladder cancer	1.04e-05	7.4e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.02e-05	7.25e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—KRAS—urinary bladder cancer	1.02e-05	7.21e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCND1—urinary bladder cancer	1.02e-05	7.21e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.01e-05	7.19e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.01e-05	7.17e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.01e-05	7.16e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1e-05	7.11e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	9.91e-06	7.04e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	9.89e-06	7.02e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MMP9—urinary bladder cancer	9.86e-06	7e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.86e-06	7e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	9.82e-06	6.98e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	9.82e-06	6.98e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PTEN—urinary bladder cancer	9.8e-06	6.96e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	9.72e-06	6.9e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MYC—urinary bladder cancer	9.64e-06	6.85e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—EP300—urinary bladder cancer	9.61e-06	6.83e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—EGFR—urinary bladder cancer	9.43e-06	6.7e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.4e-06	6.68e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—EP300—urinary bladder cancer	9.35e-06	6.64e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	9.32e-06	6.62e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	9.23e-06	6.56e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PPARG—urinary bladder cancer	9.2e-06	6.54e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—SRC—urinary bladder cancer	9.09e-06	6.46e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—TYMS—urinary bladder cancer	9.03e-06	6.42e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TP53—urinary bladder cancer	9.03e-06	6.41e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.99e-06	6.39e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	8.93e-06	6.34e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	8.93e-06	6.34e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—KRAS—urinary bladder cancer	8.91e-06	6.33e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	8.84e-06	6.28e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—HRAS—urinary bladder cancer	8.63e-06	6.13e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GPX1—urinary bladder cancer	8.55e-06	6.07e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	8.55e-06	6.07e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	8.4e-06	5.96e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	8.36e-06	5.94e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PPARG—urinary bladder cancer	8.21e-06	5.83e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MYC—urinary bladder cancer	8.15e-06	5.79e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.02e-06	5.69e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—EGFR—urinary bladder cancer	7.97e-06	5.66e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TP53—urinary bladder cancer	7.92e-06	5.62e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	7.89e-06	5.61e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	7.89e-06	5.6e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.7e-06	5.47e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—HRAS—urinary bladder cancer	7.57e-06	5.38e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	7.55e-06	5.37e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—KRAS—urinary bladder cancer	7.53e-06	5.35e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.5e-06	5.33e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PPARG—urinary bladder cancer	7.49e-06	5.32e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTEN—urinary bladder cancer	7.46e-06	5.3e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTEN—urinary bladder cancer	7.29e-06	5.18e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	7.26e-06	5.15e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	7.24e-06	5.14e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	7.19e-06	5.11e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—EP300—urinary bladder cancer	7.11e-06	5.05e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.97e-06	4.95e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—EP300—urinary bladder cancer	6.95e-06	4.94e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.89e-06	4.9e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.89e-06	4.9e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TP53—urinary bladder cancer	6.69e-06	4.75e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.6e-06	4.69e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.48e-06	4.6e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	6.46e-06	4.59e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PPARG—urinary bladder cancer	6.4e-06	4.55e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—HRAS—urinary bladder cancer	6.4e-06	4.54e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTEN—urinary bladder cancer	6.31e-06	4.48e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.31e-06	4.48e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	6.15e-06	4.37e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.09e-06	4.33e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—EP300—urinary bladder cancer	6.02e-06	4.28e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	5.94e-06	4.22e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	5.89e-06	4.18e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTEN—urinary bladder cancer	5.63e-06	4e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.5e-06	3.91e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—EP300—urinary bladder cancer	5.37e-06	3.82e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—EP300—urinary bladder cancer	5.24e-06	3.73e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	5.18e-06	3.68e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTEN—urinary bladder cancer	5.14e-06	3.65e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	5.03e-06	3.58e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.94e-06	3.51e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.94e-06	3.51e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—EP300—urinary bladder cancer	4.9e-06	3.48e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.74e-06	3.37e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTEN—urinary bladder cancer	4.39e-06	3.12e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—EP300—urinary bladder cancer	4.19e-06	2.97e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.88e-06	2.76e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.39e-06	2.41e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.23e-06	2.3e-05	CbGpPWpGaD
